Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vancomycin prophylaxis for hospital-onset Clostridioides difficile infection in high-risk inpatients
TCTR20250328002Phase 2Completed
- Sponsor
- Thammasat University
- Start
- Apr 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vancomycin in Clostridioides difficile colitis (CDI), sponsored by Thammasat University. Started Apr 2024; status: completed.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on TCTR20250328002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250328002.